Jaakko Rissanen Presidentqsb.webcast.fi/o/orion/orion_2015_0526_cmd_09/CMD2015_09.pdf · Healthcare...

Orion Diagnostica

Jaakko Rissanen

President

Orion Diagnostica

• In 2014 net sales 56.4 m€ (-1%)*

• Over 80% from international sales

• Operating profit 6.4 m€ (+38%)

• Main market areas: Europe (especially northern), China, USA, Japan

• Own Sales Units in Finland, Sweden, Norway, Denmark, Czech

Republic, Slovak Republic, Poland, Hungary and Germany

• Distributor network covering over 60 countries

• Personnel about 300 of which 50 outside Finland

• Compliance with high quality and regulatory requirements:

ISO 9001, ISO 13485 and FDA

26 May 2015 2 Orion Capital Markets Day 2015

Figures in

a nutshell

* comparison figures of 2013 include sales of products that were discontinued in 2013.

Smart Solutions for

Healthcare & Hygiene Monitoring


Orion Diagnostica is a mid-

sized, reliable European IVD

company with over 40 years

experience.

We develop, manufacture and

market diagnostic test systems for

healthcare professionals especially

in point-of-care.

HUMAN IVD MARKET (Kalorama, 2013 figures) USA Europe China Japan ROW Global CAGR

USD billion %

Global IVD market 24.4 15.2 1.7 4.8 8.5 54.6 4

- Professional POC 6.0 4

- POC for OTC and self-testing 8.9

- Core lab 39.7

Global POC market (Prof & OTC) - Professional POC

9.8

5.1

7.0

2.6

0.9

5%

1.2

6%

18.8

7.8 5

Global infectious diseases 13.4

- Professional POC

- POC as reference, (Alere estim)

0.9

1.5

4.4

- Core lab 12.5 5

Global MDx market 3.2 1.2 0.2 0.6 0.5 5.7 8

- POC MDx market 1.9 0.3 3% 10% 8% 2.2

Global MDx inf diseases market - POC MDx market

3.0

0.7 8


We operate in the IVD growth segments

Our customers

Point-of-Care Small and mid-size Infection control,

laboratories industrial microbiology


A forerunner in point-of-care

systems with immunological IVD

POC products deployed already in

the 1990s.

Our flagship product with ca 40.000

units installed globally, is the rapid,

easy-to-use QuikRead go® CRP.

Orion Diagnostica – Building well-being


QuikRead go® CRP

Your support in treatment decisions


wrCRP

wrCRP+Hb

CRP

CRP+Hb

hsCRP+Hb

Strep A

iFOBT

More to follow…

Helps to target antibiotic treatment to those who really need it

Reduced risk for antibiotic resistance and cost savings in healthcare

Our newest platform on the European markets is

Orion GenRead®. It is based on SIBA®, a novel

isothermal molecular diagnostics technology.

It brings flexible and easy detection of pathogens

for laboratories of various settings and sizes.

The first tests with low sample preparation

requirements target gastrointestinal pathogens,

e.g. C. difficile and Salmonella.

Orion Diagnostica – Building well-being


Conventional PCR vs. Isothermal NAT Some features as presented in 2013


++

2015

++

++

++

SIBA® – Benefits


Orion GenRead®

Molecular testing for healthier life


C. difficile

Salmonella

More to follow…

Based on SIBA®, a novel isothermal molecular diagnostics technology

Flexible and easy pathogen detection for any laboratory

Market Entry in In Vitro Diagnostics

COUNTRY X

Sales channel

Clinical acceptance

Laboratory acceptance

Payer exists

Trial(s) at end user

Procurement process

Purchase decision

ROUTINE USE =


SALES CAN START!

Market Entry in In Vitro Diagnostics


• Effective building of a distribution network can typically start only when the product is

ready (~customer validation phase)

• All steps need to be covered in each country before sales can start

Country Sales channel

Clinical

acceptance

Laboratory

acceptance Payer exists

Trial use

at end user

Procurement

process Purchase Routine use

1

2

3 SALES !

4

5

6

7

.

.

n


Thank you!

Jaakko Rissanen Presidentqsb.webcast.fi/o/orion/orion_2015_0526_cmd_09/CMD2015_09.pdf · Healthcare...

Documents

Transcript of Jaakko Rissanen Presidentqsb.webcast.fi/o/orion/orion_2015_0526_cmd_09/CMD2015_09.pdf · Healthcare...